Parkinson's Disease Neuroprotection Clinical Centers

帕金森病神经保护临床中心

• 批准号: 8033820
• 负责人: JOHN FANG
• 金额: $ 4.55万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2012-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8033820
• 关键词: Blood; Cerebrospinal Fluid; Clinical; Clinical Trials; Collaborations; Disease; Disease Progression; Future; Genetic; Lead; Liquid substance; Movement Disorders; Multicenter Trials; Neurologist; Parkinson Disease; Patients; Research; Research Infrastructure; Sampling; Severities; Site; Training; neuroprotection; pilot trial; prevent

DESCRIPTION (provided by applicant): As outlined in this RFA (RFA-NS-02-010) announcement, the aims of this project are to create a clinical center for the conduct of future clinical trials of neuroprotection for Parkinson's disease. This site has three board-certified neurologists trained in movement disorders who will participate in this proposed project. Upon implementation of this project these neurologists will collaborate to conduct a pilot trial of an agent to prevent disease progression in PD. Subsequently, additional collaboration with the other clinical center sites will lead to at least one multicenter trial. This project will help to maintain a stable infrastructure for the administration of the clinical trial(s) in neuroprotection related to Parkinson's disease. In addition, the conduct of this type of clinical trial(s) will generate a sample of patients with early PD who may be willing to participate in genetic studies. Similarly, subjects may be willing to participate in studies to identify markers from blood or cerebrospinal fluid that may indicate disease presence or severity. This research may lead to a greater understanding of PD and better treatments.

描述（由申请人提供）：正如本 RFA (RFA-NS-02-010) 公告中所述，该项目的目标是创建一个临床中心，用于未来开展帕金森病神经保护临床试验。该网站拥有三名经过委员会认证的神经科医生，他们接受过运动障碍方面的培训，他们将参与这个拟议的项目。该项目实施后，这些神经科医生将合作进行一项药物试点试验，以预防帕金森病的进展。随后，与其他临床中心站点的额外合作将导致至少一项多中心试验。 该项目将有助于维持与帕金森病相关的神经保护临床试验管理的稳定基础设施。此外，进行此类临床试验将产生可能愿意参与基因研究的早期 PD 患者样本。同样，受试者可能愿意参与研究，以识别血液或脑脊液中可能表明疾病存在或严重程度的标记物。这项研究可能会导致人们对帕金森病有更深入的了解并获得更好的治疗方法。